Dear editor, Although Parkinson's dis ease (PD) is mainly a sporadic disorder, there is a demonstrable familial occur rence in up to 30% of cases [1] . Thanks to the improv ing of molecular genetics technologies, the list of identifiable genetic mutations related to genetic forms of PD is ever broader. In general, these are label led with the abbreviation PARK with a number refl ect ing the chronological order in which they were discovered (to date PARK 1-23) [2] . Although we know the gene loci of all cur rently known PARK dis eases, we do not yet know all of their causative genes.
We describe a 59-year-old woman with a history of 7 years of anxious depres sive disorder, insomnia and personality disorder with paranoid behaviour (documented as a depres sive type of schizoaf fective disorder), treated with various types of antidepres sants and antipsychotics, including clonazepam, cinolazepam, mirtazapine, venlafaxine, alprazolam and risperidone. She is cur rently tak ing olanzapine, venlafaxine and alprazolam. Her psychological asses sment showed cognitive decline and organicity, without signifi cant evidence of psychosis. She was examined for the fi rst time at the age of 57, when she complained of left hand clumsiness and nonspecific leg weakness when walking, occur r ing for about 2 years, short-term memory los s, urinary frequency and orthostatic problems. Initial ly, we suggested a neuroleptic-induced parkinsonism. However, the patient referred to a history of adult-onset parkinsonism in more family members on her mother's side, some with clear benefi t after levodopa treatment ( Fig. 1 ). On examination, there was a hypokinetic-rigid syndrome, more on the left side, with slight postural tremor of the left hand, hypomimia, seboroic dermatitis and positive Babinski sign on the left. Magnetic resonance imaging of the brain displayed slightly asym metric frontoparietal atrophy (more on the left) and incipient leukoencephalopathy. Electroencephalography showed theta activity with sporadic delta dysrhythmia on the right side. Dopamine transporter singlephoton emission computed tomography (DaT-SPECT) confi rmed the reduced uptake of presy nap tical dopaminergic neurons, thus a neurodegenerative parkinsonism. A slitlamp examination for the presence of a Kayser-Fleischer r ing was negative. The patient was extensively tested neurological ly and neuropsychological ly (Tab. 1). She started to take rasagiline, with no subjective improvement. A levodopa trial was then initiated with improvement of her parkinsonism at a dose of 750 mg daily. Ow ing to suspicion of hav ing a familial form of parkinsonism, we conducted genetic testing.
The patient's DNA was isolated from peripheral blood. The amplicon library was in-silico-, designed by Ion AmpliSeq Designer (Thermo Fisher Scientifi c, Waltham, USA) for the ADH1C, EIF4G1, FBXO7, GBA + + GBAP1, GIGYF2, HTRA2, LRRK2, MAPT, PARK2, PARK7, PINK1, PLA2G6, SNCA, UCHL1 and VPS35 genes. In total 617 amplicons covered 92.59% of the cod ing DNA sequence, including 100 bp into the introns and both 5' and 3' UTRs of the particular gene regions. After fi lter ing the variants, two mis sense and one synonymous rare mutation were found (Tab. 1). The most important mutation was found in exon 21 in a coiled coil domain of the GIGYF2 gene on chromosome 2 (c.2384G>A; p.Arg795His), which has not been published until now. Since the majority of symp tomatic family members includ ing the patient's brother have died, the patient is childless and cooperation with her is quite diffi cult, extensive genetic family test ing is, unfortunately, not pos sible.
In 2002, Pankratz et al identified, by way of whole-genome linkage analysis, a locus for a new genetic form of PD [3] . The locus on chromosome 2 (2q36-37) cor responds with the 18-cM interval between the Cesk Slov Ne urol N 2017; 80/ 113(6): 719-721 microsatel lite markers D2S396 and D2S338, which contains 73 potential candidate genes. In this region, the gene encod ing a protein with 1,299 amino acids, named GIGYF2 (Grb10-Interact ing GYF protein 2), was found. Both known homologues, GIGYF1 and GIGYF2, interact by their GYF domain with the proline-rich region of Grb10 adaptor protein [4, 5] . Although it is hypothesized that GYF-domain-containing proteins take part in mRNA splic ing or other steps of mRNA proces sing, the exact function of the GIGYF2 protein is not yet known [4] . Lautier et al. [4] have studied all 27 exons of the GIGYF2 gene in 249 PD patients with at least one af fected firstdegree relative in comparison to 227 control subjects. In the PD group there were seven heterozygous mutations in 12 unrelated identified cases. These mutations were consistent with autosomal dominant adult onset levodopa--responsive PD with incomplete penetrance. The GIGYF2 gene was then added to the candidate genes for a monogenic form of PD, later designated as PARK 11. Nichols et al. careful ly examined a sample of 566 familial PD cases with nearly 1,500 aff ected individuals for these seven variants. Additional ly, another three new mutations were discovered. All these variants PhyloP -bioinformatic tool for evaluating of phylogenetic conservation; PolyPhen -bioinformatic tool for prediction of nonsynonymous variants (Polymorphism Phenotyping v2); SIFT -bioinformatic tool for prediction of nonsynonymous variants (sorts intolerant from tolerant); MAFminor allele frequency; 1000 G -allele frequency based on 1000 Genomes Project proLékaře.cz | 5.2.2020 were found in only six PD families, and the authors believe they are not responsible for the heredity of PD at the 2q36-37 locus [5] .
Haplotype analysis of the GIGYF2 gene proved that mutations are not as sociated with a higher risk of sporadic PD [6] . In an animal study, abrogation of GIGYF2 function in zebrafi sh did not lead to a loss of diencephalic dopaminergic cel ls, suggest ing that this gene is probably not required for dopaminergic differentiation of cel ls [7] . Afterwards, another study which questioned the role of the GIGYF2 gene in causal relation to familial PD and its as sociation with PARK 11 dis ease started to appear [8, 9] . Therefore in the contemporary literature, the mutations in the GIGYF2 gene no longer appear as a cause of PARK 11 dis ease [10] .
We report here a patient with pos sible autosomal dominant PD with incomplete penetrance with genetical ly confirmed mutation in the GIGYF2 gene. Unfortunately, the patient's symp tomatic and asymptomatic relatives were not clinical ly or genetical ly tested. In our patient, psychiatric manifestation (depres sion, paranoid behaviour and cognitive decline) preceded her motor symp toms by some years. They more likely represent as sociated symptoms in PD rather than simple coexistence of a schizoaff ective disorder with PD. Psychiatric symp toms in car riers of the GIGYF2 mutation have thus far not been reported. As previously mentioned, the causality of GIGYF2 mutation in PARK 11 dis ease has been disproved [10] . However, there is a need to answer two principal questions: 1. What other gene mutation could be responsible for the develop ing of the dis ease? 2. What is a result of GIGYF2 mutation in our patient, if it is not pathogenic? Therefore, we believe that further studies to solve this problem are neces sary.
